1. Home
  2. IMTE vs PFSA Comparison

IMTE vs PFSA Comparison

Compare IMTE & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integrated Media Technology Limited

IMTE

Integrated Media Technology Limited

N/A

Current Price

$0.50

Market Cap

2.0M

ML Signal

N/A

PFSA

Profusa Inc.

HOLD

Current Price

$0.27

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMTE
PFSA
Founded
2008
2009
Country
Australia
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.7M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
IMTE
PFSA
Price
$0.50
$0.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.2K
167.6K
Earning Date
10-22-2024
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.05
52 Week High
$1.54
$4.22

Technical Indicators

Market Signals
Indicator
IMTE
PFSA
Relative Strength Index (RSI) 45.21 27.37
Support Level $0.51 $0.07
Resistance Level $0.57 $0.41
Average True Range (ATR) 0.05 0.03
MACD 0.00 0.00
Stochastic Oscillator 72.50 4.91

Price Performance

Historical Comparison
IMTE
PFSA

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: